PubMed · 15292383
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
Sarah L Zielinski. 2004-08-04. Project creates repository for microarray datasets.. https://doi.org/10.1093/jnci%2F96.15.1126
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
The low-energy electron spectra generated in the decay of 140Nd have been measured using a combined electrostatic spectrometer adjusted to the 4, 7, and 35 eV instrumental resolution. In order to estimate the therapeutic potential of low-energy electrons associated with the decay of 140Nd, similar experiments have been performed with 111In. Relative Auger electron intensity ratios per decay are: 111In(K-Auger)/140Nd(K-Auger)=1.47(12), 111In(L-Auger) /140Nd(L-Auger)=1.1(4), and 111In(L-Auger [2.8-7 keV])/140Nd(L-Auger [2.8-7 keV])=0.24(11). The obtained K-Auger group intensity ratios have been compared with results of calculations. The good agreement found for the experimental and estimated values indicates that such information can be also derived using available nuclear and atomic data. The relative intensity of L-Auger electrons emitted within the 2.8-7 keV interval is higher for 140Nd by a factor of about 4 compared to 111In. As the L-Auger emission is dominating relative to that of the K-Auger group, this implicates that any potential endotherapeutic strategy using 140Nd-labelled targeting vectors requires a maximum accumulation of the endoradiotherapeutical close to the cell nucleus or the DNA of the tumour cell.
The structure of DNA is wondrously appealing in its elegant simplicity combined with its captivating power. The power of DNA derives directly from, and solely from, the fact that it represents digital information. However, this delightful digital determinism does not carry over into the multitude of cellular processes, especially in a cancer cell. This means that the sequencing of the human genome has some limitations regarding furthering the understanding of details of cancer cell biochemistry. The fading of digital control in cells, however, seems not well comprehended by most. This factor, together with the loss of DNA stability that is an underpinning of cancer, virtually guarantees that chaotic dynamics are very important in cancer cells. Yet, chaos is very underappreciated in oncology. Failure to appreciate the significance of the dissolution of digital control in cell dynamics and the lack of perception of the importance of chaotic dynamics in the cancer cell are 2 errors that will tend to enhance the frequency of mistakes made in analyzing information from gene expression microarrays, proteomic microarrays, and other advances in molecular oncology. This article explains how these mistakes will come about and why, in some instances, they could result in adverse effects in patient therapy as the goals for targeted, individualized, and molecular-based treatments are sought.
Conventional diagnosis of prostate cancer does not appear to be sensitive enough to differentiate pre-operatively between organ-confined and extracapsular disease. New technologies, arising from the field of molecular biology, have been introduced to improve diagnosis and their implementation into the clinical practice is nowadays extensively explored. In 1992, focusing on prostate cancer, the application of the highly sensitive and specific reverse transcription-polymerase chain reaction (RT-PCR) technology which amplifies predefined mRNA species was introduced. Assuming haematogenous prostate tissue-specific mRNA species to be representative for the presence of circulating prostate cancer cells, an impressive series of clinical studies, for the greater part addressing mRNA encoding for prostate-specific antigen (PSA), were performed to improve pre-operative staging (molecular staging) and prognosis of prostate cancer, and to study iatrogenic cell dissemination. In this review we summarize the efforts, concentrating on the RT-PCR methodology, to identify extracapsular prostate cancer cells in easy accessible body fluids. The substantial amount of available biological and clinical data allow an in depth illustration of the advantages, disadvantages and clinical future of this technology. The intrinsic limitations of the technology, technical as well as biological, will be addressed since these may well explain the controversies associated with its general acceptance in the clinical practice. Together with considerable improvements of the methodology to be expected in the near future, new avenues for the detection of disseminated prostate cancer cells will be subject of discussion.